Journal of Clinical PracticeJournal of Clinical PracticeКлиническая практика2220-30952618-8627Eco-Vector824010.17816/clinpract3351-62ArticlesСтатьиReview ArticleISSUES OF ANTICOAGULANT TREATMENT MANAGEMENTВОПРОСЫ ОРГАНИЗАЦИИ ЛЕЧЕНИЯ АНТИКОАГУЛЯНТАМИZateyshchikovD AЗатейщиковДмитрий Александрович

профессор кафедры кардиологии и общей терапии МЦ Управления Делами Президента, д.м.н.

dz@bk.ruIsaevaM YuИсаеваМарина Юрьевна

врач-кардиолог КДЦ ФНКЦ ФМБА России, к.м.н.

МЦ Управления Делами Президента РоссииФНКЦ ФМБА России1509201233NO3 (2012)№3 (2012)516216032018Copyright ©; 2012, Zateyshchikov D.A., Isaeva M.Y.Copyright ©; 2012, Затейщиков Д.А., Исаева М.Ю.2012Zateyshchikov D.A., Isaeva M.Y.Затейщиков Д.А., Исаева М.Ю.https://creativecommons.org/licenses/by-nc-nd/4.0https://clinpractice.ru/clinpractice/article/view/8240

The review provides information about various aspects of anticoagulant treatment organization. The recommendations concerning the organization of a specialized anticoagulant service are discussed. The rules of patient education, the choice of anticoagulant dosage control are described. Authors provide data of the cost-effectiveness of anticoagulants.

В обзоре собраны сведения, касающиеся разных аспектов организации лечения антикоагулянтами. Рассмотрены рекомендации, касающиеся организации специализированной антикоагулянтной службы. Разбираются правила контроля качества лечения. Описаны правила обучения больного, выбора способа контроля дозировки антикоагулянта. Приведены данные об экономической эффективности применения антикоагулянтов.

anticoagulantsanticoagulant servicecontrol INRантикоагулянтыантикоагулянтная службаконтроль МНОStowasser D. A, MO'Leary K. Understanding the Medicines Management Pathway. Journal of Pharmacy Practice and Research 2004;Volume 34, :293-296.Bajorek B. A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks. Therapeutic Advances in Drug Safety 2011;2:45-58.Hall D, Buchanan J, Helms B, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy 2011;31:686-694.Сычев Д.А., Гаврисюк Е.В., Поликарпова О.А. Методология создания и функционирования центров персонализированной антикоагулянтной терапии: взаимодействие лабораторных и клинических методов повышения эффективности и безопасности фармакотерапии. Справочник заведующего клинико-диагностической лабораторией, 2011;1 3-5.Hendriks JM, de Wit R, Crijns HJ, et al. Nurseled care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. European heart journal 2012.Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003;15:213-216.Okumura K, Komatsu T, Yamashita T, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and infuential factors. Circulation journal: official journal of the Japanese Circulation Society 2011;75:2087-2094.Lind M, Fahlen M, Kosiborod M, et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res 2012;129:32-35.Rose AJ, Hylek EM, Berlowitz DR, et al. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circulation Cardiovascular quality and outcomes 2011; 4:276-282.Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. European heart journal 2011; 32: 2282- 2289.Indicators for Quality Use of Medicines in Australian Hospitals: NSW Therapeutic Advisory Group. http://wwwciaphealthnswgovau/nswtag/ 2007.Ghate SR, Biskupiak JE, Ye X, et al. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. Ann Pharmacother 2011; 45:701-712.Fitzmaurice DA, Gardiner C, Kitchen S, et al. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. British journal of haematology 2005;131:156-165.Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322-334.Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. The New England journal of medicine 2010;363:1608-1620.Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011;154:472-482.Plesch W, Wolf T, Breitenbeck N, et al. Results of the performance verification of the CoaguChek XS system. Thromb Res 2008;123:381-389.Sobieraj-Teague M, Daniel D, Farrelly B, et al. Accuracy and clinical usefulness of the CoaguChek S and XS Point of Care devices when starting warfarin in a hospital outreach setting. Thromb Res 2009;123:909-913.Solvik UO, Petersen PH, Monsen G, et al. Discrepancies in International Normalized Ratio Results between Instruments: A Model to Split the Variation into Subcomponents. Clin Chem 2010; 56: 1618-1626.Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. British journal of haematology 2011;154:311-324.Platt AB, Localio AR, Brensinger CM, et al. Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest 2010;137:883-889.Bushnell CD, Olson DM, Zhao X, et al. Secon- dary preventive medication persistence and adherence 1 year after stroke. Neurology 2011;77:1182-1190.Белоусов Ю.Б., Явелов И.С., Белоусов Д.Ю., Афанасьева Е.В. Анализ прямых затрат, ассоциированных с применением варфарина у пациентов с фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии 2011;7:561-566.Atay JK, Fiumara K, Piazza G, Fanikos J, Goldhaber SZ. Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2012;18:181-184.Ягудина Р.И., Куликов А.Ю., Тихомирова А.В. Возможность переноса фармакоэкономических данных из страны в страну. Фармакоэкономика 2009;2:8-18.Белоусов Ю.Б., Мареев В.Ю., Явелов И.С., Белоусов Д.Ю. Фармакоэкономический анализ эффективности дабигатрана этексилата у пациентов с неклапанной фибрилляцией предсердий. Кардиология 2012;51:44-51.Белоусов Ю.Б., Мареев В.Ю., Явелов И.С., Белоусов Д.Ю.Клинико-экономический анализ эффективности дабигатрана этексилата в сравнении с варфарином в аспекте профилактики сердечно-сосудистых осложнений у пациентов с неклапанной фибрилляцией предсердий. Рациональная фармакотерапия в кардиологии 2012;8:37-44.Jacobs JW, Bernhard MR, Delgado A, Strain JJ. Screening for organic mental syndromes in the medically ill. Ann Intern Med 1977;86:40-46.McHorney C, Ware J, Raczek A. The MOS 36- Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263